BIA is pleased to announce the appointment of Lucy Foley, Chief Technology Officer at eXmoor Pharma, as Vice Chair of its Manufacturing Advisory Committee (MAC).
Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.
Coulter Partners successfully completed a search assignment for Tozaro and is pleased to announce the placement of Dr. Jason Slingsby, MBA as Chief Executive Officer.
We are calling on the UK government to mandate pension funds to invest in high-growth UK sectors, as new data from its latest report shows British pension schemes are still missing from the biggest biotech deals.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.
Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
Symbiosis, a global biopharmaceutical CMO specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category.
ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has revealed the keynote speakers for its flagship event, Drug Discovery 2025
Ikarovec, which is developing field-changing bicistronic gene therapies for ophthalmic diseases, appoints Dr Thomas Ciulla, expert in ophthalmology drug development, as President and CEO.
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
The BIA has coined the term ‘Deep Biotech’ to capture companies working in this biotech space. This explainer explores the disruptive impact of biology-powered Deep Biotech products and processes, their role in tackling climate change, and how the BIA is driving forward the biorevolution in the UK.
PIR International recently partnered with Monument Therapeutics in appointing Robert Radie as Non-Executive Chair and Dr. Heather Preston as an Advisory Board Member.
NCIMB Limited ("NCIMB") has secured a £1.7m investment from the Investment Fund for Scotland, managed by Maven Capital Partners (“Maven”) and the Scottish National Investment Bank.
Microbiotica has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30.
